Six big U.S. pharmaceuticals giants are set to report Q4 earnings in coming days, and Credit Suisse analyst Vamil Divan just released a report previewing what traders can expect. Starting on Jan. 26, Johnson & Johnson (NYSE: JNJ), Eli Lilly and Co (NYSE: LLY), Bristol-Myers Squibb Co (NYSE: BMY), AbbVie Inc (NYSE: ABBV), Pfizer Inc. (NYSE: PFE) and Merck & Co., Inc. (NYSE: MRK) all report earnings within a one-week stretch.

Overall, Divan expects that the market will be most concerned with the path forward for these companies. “We expect investor focus to be primarily on company guidance and commentary around 2016 as opposed to the actual 4Q 2015 results,” he explained.

Related Link: Credit Suisse Initiates On Smid-Cap Biotechs, Reveals Favorite Stock Picks

While the firm is bullish on the space overall, it remains cautious on Merck, which is facing new generic competition for Vytorin/Zetia in 2017.

Headed into earnings season, Credit Suisse has an Outperform rating on AbbVie, Bristol Myers, Eli Lilly and Pfizer. The firm maintains a Neutral rating on J&J and Merck.

Disclosure: the author holds no position in the stocks mentioned.

Latest Ratings for JNJ

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

See more from Benzinga

• 2 Pair Trades: Goldman Over JPMorgan, Schwab Over Raymond James

• Bollinger Band Breakdown For These 3 Stocks

• How To Invest In The Digital Age With The 'Internet Titans' ETF

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.